Epidemiology of ST131 in Besançon University Hospital

The sequence type 131 (ST131) is a predominant lineage among extraintestinal pathogenic Escherichia coli. It plays a major role in the worldwide dissemination of E. coli that produce extended-spectrum beta-lactamase (ESBL). The aim of this study was to describe the epidemiology of ESBL producing ST131clonal group in our university hospital. All patients with an infection due to ESBL E. coli will be prospectively included for a 2-year period. ST131 isolates will be identified and risk factors associated to ST131 will be determined in comparison to non-ST131 ESBL E. coli.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Escherichia Coli Infections Bacterial Infections Bacterial Infections and Mycoses Enterobacteriaceae Infections Gram-Negative Bacterial Infections Infections

Sex eligibility

All sexes

Study type

Observational

Primary location

Centre Hospitalier Régional Universitaire

Besançon, 25030, France

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Patients infected with ESBL producing E. coli

Exclusion criteria

Patients known to be carrier or infected in the previous year, patients only colonised with ESBL producing E. coli.

Treatment and study plan

Primary outcomes

Risk factors associated to ESBL ST 131 infections

Time frame: up to 2 years

Time of hospitalization

Sponsors and collaborators

Lead sponsor

Centre Hospitalier Universitaire de Besancon

Other

Registry information

Acronym: coliST131

Important dates

Study start: 2015
Primary completion: 2017
Study completion: 2017
First posted: Aug 3, 2016
Registry last updated: Oct 17, 2017

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed